Liège, Belgium 18 November 2015 – Regulated information: Mithra Pharmaceuticals, leader in Women’s Health and cutting-edge technological company in the field of API slow-release drugs based on polymere (subcutaneous implants, biocompatible rings, hormonal IUD’s), announced today that it has enrolled the last patient required in the pharmacodynamics & pharmacokinetics studies of its Zoreline® subcutaneous implant 10.8 mg.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024